(RTTNews) - Genentech, a member of the Roche Group (RHHBY), said Thursday that it will present new data for its approved and investigational medicines for the treatment of neurological disorders at the 73rd American Academy of Neurology Annual Meeting being held virtually April 17-22, 2021.
Genentech noted that the new data include 23 abstracts highlighting the expanding the company's neuroscience portfolio across six therapeutic areas, including Evrysdi (risdiplam) for spinal muscular atrophy, Ocrevus (ocrelizumab) in relapsing and primary progressive multiple sclerosis, investigational Bruton's tyrosine kinase inhibitor fenebrutinib in Phase III trials for RMS and PPMS, Enspryng (satralizumab-mwge) in neuromyelitis optica spectrum disorder or NMOSD, and data from investigational programs in Alzheimer's disease or AD and Huntington's disease or HD.
The company said it will present data from five studies from the Evrysdi clinical development. The program was designed to represent a broad spectrum of people living with Spinal Muscular Atrophy or SMA. The program includes infants aged 2 months to adults aged 60 years with varying degrees of disability, including people with scoliosis or joint contractures, and those previously treated for SMA with another medication.
The company stated that new 2-year findings from Part 2 of the Phase II/III FIREFISH trial show longer-term efficacy and safety of Evrysdi in infants with symptomatic Type 1 SMA treated with Evrysdi.
Genentech will present data from its Multiple Sclerosis or MS franchise, including five presentations covering Ocrevus and results from studies on the investigational BTKi fenebrutinib.